3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
4
Completed
3
Active not recruiting
3
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Hepatocellular
23
Carcinoma, Non-Small-Cell Lung
4
Liver Neoplasms
3
Pancreatic Neoplasms
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Cholangiocarcinoma
2
Biliary Tract Neoplasms
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma
1
Liver Cirrhosis
1
Hepato Cellular Carcinoma
1
Endometrial Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma
1
Adenocarcinoma Of Esophagus
1
Interventions
pembrolizumab
20
Gemcitabine
18
Cisplatin
14
Magnetic Resonance Spectroscopy
13
enfortumab vedotin
12
Specimen Handling
10
Cystectomy
10
Docetaxel
8
Mitomycin
7
Standard of Care
6
Cystoscopy
6
Transurethral Resection of Bladder
5
Radiotherapy
5
Carboplatin
5
durvalumab
4
Practice Guidelines as Topic
4
Nivolumab
4
Radiation
3
Multiparametric Magnetic Resonance Imaging
3
Mitozytrex
3
Fluorouracil
3
tislelizumab
2
dehydroftorafur
2
cemiplimab
2
avelumab
2
alvimopan
2
Therapeutics
2
Surveys and Questionnaires
2
Surgical Procedures, Operative
2
Radiosurgery
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Urinary Bladder Neoplasms
×
tremelimumab
×
Clear all
NCT03317158
2026-04-15
ADAPT-BLADDER
Hoosier Cancer Research Network
Phase 1/2
Recruiting
55 enrolled